{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"RR is defined as a binary variable. A success will be defined as patient who achieve a response of a partial response (PR) or better using the International Myeloma Working Group (IMWG) criteria. Biomarkers of interest will be identified and categorized into clinically relevant groups (e.g. positive vs. negative) by evaluating baseline and post treatment (after cycle one) biospecimens. RR will be estimated within each biomarker. Each cohort (A-D) will be evaluated separately and independently.","groups":[{"description":"Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally","id":"OG000","title":"Cohort A (Lenalidomide, Dexamethasone)"},{"description":"Patients with newly diagnosed multiple myeloma receive treatment as in Cohort A.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally","id":"OG001","title":"Cohort B (Lenalidomide, Dexamethasone)"},{"description":"Patients with relapsed or refractory multiple myeloma receive lenalidomide PO QD on days 1-14 in combination with dexamethasone PO QD on days 1, 8 and 15 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally\n\nPomalidomide: Given orally","id":"OG002","title":"Cohort C (Lenalidomide, Dexamethasone, Pomalidomide)"},{"description":"Patients with relapsed multiple myeloma after lenalidomide maintenance receive treatment as in Cohort C.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally\n\nPomalidomide: Given orally","id":"OG003","title":"Cohort D (Lenalidomide, Dexamethasone, Pomalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients that completed the study were included in analysis","reportingStatus":"POSTED","timeFrame":"21 days","title":"Response Rates (RR) at First Assessment","type":"PRIMARY","unitOfMeasure":"Participants"}